Aligning with Toshiba, Abbott Nearly Completes its Diagnostics Line
Executive Summary
A market leader in most diagnostic technology categories, immunoassay, hematology, and blood glucose, Abbott has historically stumbled in clinical chemistry. But with customers wanting broader options from fewer suppliers, Abbott knew it had to make its move in chemistry. Earlier in 1997, it bought Alcyon Analyzer, a small French company. But with this deal with Toshiba, Abbott is poised to make a major move.
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.